What hormones are found in bovine pituitary extract?

Bovine pituitary extract contains multiple pituitary-derived hormones including somatotropin (growth hormone), prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), and adrenocorticotropic hormone (ACTH). These peptide hormones are biologically active and can bind to their respective receptors upon administration, though oral bioavailability of intact peptides remains a significant pharmacological limitation.

Is bovine pituitary extract safe from mad cow disease (BSE)?

The primary safety concern with bovine pituitary extract is the theoretical risk of contamination with prions responsible for bovine spongiform encephalopathy (BSE). Reputable manufacturers source material exclusively from countries with negligible BSE risk and use certified BSE-free herds, but no processing method completely eliminates prion risk. Consumers should verify that products carry third-party certifications and are sourced from New Zealand, Australia, or USDA-certified BSE-free operations.

What is the studied dosage of bovine pituitary extract?

In vitro research has identified 40 μg/mL as a concentration associated with increased keratocyte proliferation markers (PCNA, CD34) and reduced apoptosis (caspase-3) in bovine ovarian tissue models. No established human clinical dosage exists because controlled human trials are lacking. Commercial supplements typically provide 50–200 mg of crude glandular extract per serving, but these doses cannot be directly compared to the purified concentrations used in laboratory studies.

Can bovine pituitary extract raise growth hormone levels in humans?

There is no peer-reviewed clinical evidence demonstrating that oral bovine pituitary extract meaningfully raises circulating growth hormone (somatotropin) levels in humans. Oral peptide hormones are largely degraded by proteolytic enzymes in the gastrointestinal tract before systemic absorption can occur. While some proponents suggest a 'glandular therapy' mechanism of action, this hypothesis lacks robust human pharmacokinetic data.

Who should not take bovine pituitary extract supplements?

Individuals with hormone-sensitive cancers (e.g., estrogen-receptor-positive breast cancer, prostate cancer), active pituitary disorders such as acromegaly or pituitary adenoma, or those currently using hormone replacement therapy, insulin, or corticosteroids should avoid bovine pituitary extract due to potential hormonal interactions. Pregnant and breastfeeding women should not use this supplement as safety data are entirely absent. People with autoimmune conditions or those with concerns about prion-related diseases should also exercise caution.

What is the difference between bovine pituitary extract and synthetic growth hormone supplements?

Bovine pituitary extract is a whole-gland concentrate containing multiple hormones and bioactive compounds naturally present in cattle pituitary tissue, whereas synthetic growth hormone (recombinant hGH) is a laboratory-produced single hormone identical to human GH. Bovine extract provides a broader hormonal profile including prolactin and other peptides, but synthetic versions offer standardized, uniform dosing and are FDA-approved for specific medical conditions. The bioavailability and physiological effects of whole extract versus isolated synthetic hormone differ significantly, with extract requiring oral bioavailability considerations and synthetic GH typically requiring injection for efficacy.

Does bovine pituitary extract have bioavailability concerns when taken orally?

Yes, bovine pituitary extract faces significant bioavailability challenges as an oral supplement because pituitary hormones are peptides that are sensitive to stomach acid and digestive enzymes. Most peptide hormones are degraded in the gastrointestinal tract before absorption, which raises questions about whether orally-consumed extract can deliver active hormones systemically. Some manufacturers use enteric coating or proprietary delivery systems to address this limitation, but clinical evidence demonstrating effective oral absorption remains limited.

What does the current clinical research show about bovine pituitary extract's effectiveness in humans?

Most evidence for bovine pituitary extract comes from in vitro (laboratory cell) and animal studies, which have shown effects on prolactin release, cellular proliferation markers, and apoptosis reduction in bovine tissues. Human clinical trials are notably sparse, and the preliminary laboratory findings have not been robustly translated into proven human health outcomes. The gap between in vitro promise and human efficacy data means claims about human benefits remain largely speculative and require rigorous double-blind, placebo-controlled trials for substantiation.

Bovine Pituitary Extract (Bos taurus)

Bovine pituitary extract is a glandular supplement derived from the pituitary glands of cattle (Bos taurus), containing bioactive peptides including growth hormone, prolactin, and various trophic hormones. It acts primarily by delivering pituitary-derived signaling molecules that may influence cellular proliferation, hormone secretion, and tissue repair pathways.

Category: Protein Evidence: 2/10 Tier: Emerging

Bovine Pituitary Extract (Bos taurus) — Hermetica Encyclopedia

Origin & History

Bovine Pituitary Extract (BPE) is derived from the pituitary glands of domestic cattle (Bos taurus), collected post-mortem from slaughtered animals at abattoirs. The extraction process involves acidic extraction for posterior pituitary components or direct supplementation, yielding a mixture rich in hormones like FSH, LH, and various growth factors.

Historical & Cultural Context

BPE has no documented traditional medicine use in historical systems like Ayurveda or TCM. It is a modern extract developed primarily for research and cell culture applications since the 1970s, with early studies from 1939 exploring pituitary extracts for enhancing milk production in dairy cows.

Health Benefits

• Supports cellular protection in laboratory settings - reduced apoptosis markers (caspase-3) in bovine ovarian tissue studies (preliminary evidence)
• Promotes cellular proliferation - increased keratocyte growth markers (PCNA, CD34) at 40 μg/mL in vitro (preliminary evidence)
• Stimulates prolactin release - posterior pituitary extracts showed activity in bovine cell cultures (preliminary evidence)
• Provides antioxidant protection - demonstrated protection against H2O2-induced damage in prostate cells in vitro (preliminary evidence)
• Enhances hormone receptor expression - increased FSH and LH receptor expression in vitrified bovine follicles (preliminary evidence)

How It Works

Bovine pituitary extract contains endogenous peptide hormones—including somatotropin (growth hormone), prolactin, thyroid-stimulating hormone (TSH), and gonadotropins—that interact with membrane-bound receptors such as the growth hormone receptor (GHR) and prolactin receptor (PRLR), activating downstream JAK2/STAT5 signaling cascades. At concentrations of approximately 40 μg/mL in vitro, the extract upregulates proliferating cell nuclear antigen (PCNA) and CD34 expression, indicating stimulation of the cell cycle and angiogenic signaling. Additionally, caspase-3 suppression observed in bovine ovarian granulosa cell studies suggests anti-apoptotic activity potentially mediated through PI3K/Akt survival pathways.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted with BPE. All available research consists of preclinical animal tissue and cell culture studies, including bovine ovarian tissue preservation (PMCID: PMC12745065), keratocyte proliferation assays (PMCID: PMC3874512), and prolactin release studies (PMID: 15819972).

Clinical Summary

Current evidence for bovine pituitary extract is largely preclinical and limited to in vitro and animal models. In vitro studies using bovine ovarian granulosa cells demonstrated reduced caspase-3 apoptosis markers and increased PCNA and CD34 expression at 40 μg/mL, suggesting cytoprotective and proliferative effects. Corneal keratocyte studies support growth-promoting activity at similar concentrations, though no large-scale human randomized controlled trials have been published to date. The overall evidence base remains preliminary, and extrapolating in vitro findings to human supplementation outcomes requires significant caution.

Nutritional Profile

Bovine Pituitary Extract (BPE) is a complex biological mixture derived from Bos taurus anterior and/or posterior pituitary glands. Protein content is the dominant macronutrient, comprising approximately 60-80% of dry weight, consisting of a heterogeneous mix of peptide hormones and structural proteins. Key bioactive proteins and peptides include: Growth Hormone (GH/somatotropin, ~10-20% of anterior pituitary protein content), Prolactin (PRL, ~10-15% of anterior pituitary protein), Follicle-Stimulating Hormone (FSH), Luteinizing Hormone (LH), Adrenocorticotropic Hormone (ACTH, ~10-20 μg/mg extract), Thyroid-Stimulating Hormone (TSH), and Vasopressin/Oxytocin from posterior pituitary fractions. Growth factors present include Fibroblast Growth Factor (FGF, ~150-200 ng/mg), Epidermal Growth Factor (EGF), and Insulin-like Growth Factor-1 (IGF-1). Lipid content is modest at approximately 5-15% dry weight, including phospholipids and cholesterol integral to membrane-derived fractions. Carbohydrate content is low (~2-5%), primarily as glycoprotein-associated oligosaccharides on FSH, LH, and TSH. Mineral content includes zinc (~15-25 μg/g, relevant to hormone stabilization), copper, and trace selenium. Commercial preparations used in cell culture (e.g., Gibco BPE) are typically standardized to ~30-50 mg/mL total protein. Bioavailability when taken orally is expected to be poor due to gastrointestinal proteolysis of peptide hormones; however, smaller bioactive peptide fragments may retain partial activity. Injectable or topical formulations preserve bioactivity more reliably. Active concentrations in in vitro studies range from 20-100 μg/mL total protein.

Preparation & Dosage

No human dosage data available. In vitro studies used 200-600 μg/mL for tissue preservation (optimal 400-600 μg/mL) and 40 μg/mL for cell proliferation. No standardized forms or human dosing protocols exist. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic combinations studied, FSH supplements, LH supplements, Growth hormone precursors, Glandular extracts

Safety & Interactions

Bovine pituitary extract carries a theoretical risk of transmitting bovine-derived prion diseases such as bovine spongiform encephalopathy (BSE), making sourcing from BSE-free, certified herds critically important. Because the extract contains gonadotropins and growth hormone peptides, it may interact with exogenous hormone therapies including insulin, corticosteroids, estrogen, and testosterone, potentially amplifying or disrupting hormonal signaling. Individuals with hormone-sensitive conditions—such as acromegaly, pituitary tumors, estrogen-receptor-positive cancers, or polycystic ovarian syndrome—should avoid use without medical supervision. Safety during pregnancy and lactation has not been established, and use is not recommended in these populations.